Latest Breaking News On - Our public health solutions - Page 5 : comparemela.com

FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease

PRINCETON, N.J., Jan. 8, 2024 /PRNewswire/ Soligenix, Inc. , a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an.

Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis

Clinical Success Achieved in Second Cohort of Patients PRINCETON, N.J., Jan. 4, 2024 /PRNewswire/ Soligenix, Inc. , a late-stage biopharmaceutical company focused on developing and.

Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses

Single-vial thermostabilized bivalent vaccine demonstrates simultaneous protection against two lethal viruses PRINCETON, N.J., Jan. 2, 2024 /PRNewswire/ Soligenix, Inc. , a late-stage.

Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease In Nonhuman Primate Models Of Ebola And Marburg Viruses

"HyBryte™ Use in Early-Stage Cutaneous T-Cell Lymphoma" Published in Frontiers in Drug Discovery

HyBryte™ has potential to address a critical gap in treatment of early-stage CTCL PRINCETON, N.J., Dec. 1, 2023 /PRNewswire/ Soligenix, Inc. , a late-stage biopharmaceutical company focused on.